Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-UMIN000037307
- Lead Sponsor
- Kyushu University Department of Dermatology, Graduate School of Medical SciencesDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University
- Brief Summary
o baseline levels of biomarkers were significantly associated with EASI reduction. There were significant associations of baseline levels of LDH, Soluble IL-2 R, TARC, CCL22, CCL27, and CCL18 with POEM reduction. There were also significant associations of baseline levels of LDH, Soluble IL-2R, and TARC with pruritus-NRS reduction. Moreover, there were significant associations of baseline levels of Soluble IL-2R and TARC with uncomfortable skin-NRS reduction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 131
Not provided
(1) Patients treated with oral immunosuppressive drugs, oral steroid, or phototherapy within 4 weeks before dupilumab administration. (2) Female patients who are breastfeeding, pregnant, or have the possibility of being pregnant. (3) Any other patients who are regarded as unsuitable for this study by the investigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association between "baseline levels of 18 biomarkers" and "% change from baseline of EASI at 16w of dupilumab treatment."
- Secondary Outcome Measures
Name Time Method